Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04129905
Other study ID # CHUBX 2018/04
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 22, 2019
Est. completion date December 14, 2021

Study information

Verified date February 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Left ventricular obstruction is an invalidating complication of hypertrophic cardiomyopathies (HCM), and endothelial dysfunction has also been observed in these pathologies. However, the relation between obstruction and endothelial and venous dysfunctions has not been previously studied. The main objective is to investigate the relations between endothelial and venous dysfunctions and symptomatic left ventricular outflow-tract obstruction in HCM patients.


Description:

Hypertrophic cardiomyopathies (HCM) secondary to sarcomeric gene mutation or to Anderson-Fabry disease can be complicated by left ventricular (LV) outflow-tract obstruction responsible of disabling exercise symptoms. LV outflow-tract obstruction is a complex, multifactorial and dynamical phenomenon influenced by the degree of LV hypertrophy but also by mitral valve elongation and hemodynamical components including venous return (LV preload). The clinical and research team of Dr RĂ©ant, responsible of the Bordeaux Competence Center in hereditary or rare Cardiomyopathies, has recently demonstrated that LV outflow-tract obstruction can also be influenced by the conditions of realization of exercise echocardiography tests (position: upright versus supine, type: bicycle versus treadmill), and by an abnormal venous return capacity. In parallel, it has also been demonstrated, by other research teams, that HCM can be associated to endothelial and microvascular peripheral dysfunctions. However, to date, the relation between these two elements, and with sudden cardiac death risk, have not been previously studied. The tests which will be performed during normal recommended follow-up of the HCM patients will be: Brain Natriuretic Peptide (BNP) blood sample test, electrocardiogram (ECG), Holter ECG, echocardiography at rest and during exercise. The tests realized in addition will be: - air venous plethysmography: non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minutes. - upper member arterial Doppler echography with analysis of Flow Mediated Dilatation (FMD) : measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.. - endothelial function biomarkers: blood sample test, 5 minutes. No follow-up is required for this study.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 14, 2021
Est. primary completion date December 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients and volunteers: - Adults (age =18 years), male or female, - For female in age, efficient contraception will be required and a negative pregnancy test will be required, - Signed informed consent form will required for each included subject after having read the information note, - Affiliated to the national social security system, - Patients: .Patients diagnosed to have HCM secondary to sarcomeric mutation or to Fabry disease, symptomatic (dyspnea on exertion and/or chest pains during exercise), - Healthy volunteers: - Subjects without known cardiac disease, - No smokers. Exclusion Criteria: - Patients and volunteers: - No cardiac pathology reducing life expectancy to less than 12 months (cancer), - Unbalanced arterial hypertension (systolic >160 mmHg and/or diastolic >120 mmHg), - Pregnancy or breastfeeding, - Major obesity > 140 kg, - Impossibility or refusal to give or sign the consent form, - Subject in period of exclusion relative to an other protocol, - Subject deprived of liberty by judicial or administrative decision, - Major protected by the Law - Patients: - Atrial fibrillation at the time of inclusion - Valvulopathy with severity greater than moderate.

Study Design


Intervention

Biological:
BNP blood sample test
Performed during normal recommended follow-up of the HCM patients.
Diagnostic Test:
Electrocardiogram
Performed during normal recommended follow-up of the HCM patients.
Holter ECG
Performed during normal recommended follow-up of the HCM patients.
Echocardiography
Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
Air venous plethysmography
Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
Upper member arterial Doppler echography with analysis of FMD
Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
Biological:
Endothelial function biomarkers
Performed specifically for the research. Blood sample test, 5 minutes.

Locations

Country Name City State
France University Hospital, Bordeaux Pessac

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Bordeaux Amicus Therapeutics, Fédération Française de Cardiologie, Fondation Bordeaux Université

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of the venous ejection fraction Via a plethysmography exam. The venous ejection fraction is measured in percentage. Day 0
Primary Assessment of the caliber variation of the brachial artery Via a recording of arterial Doppler echography with analysis of FMD parameters. This parameter is measured in percentage. Day 0
Primary Measure of the Willebrand factor The analysis of this biomarker of endothelial function is performed via a peripheral venous sample.
This biomarker is measured in percentage.
Day 0
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT04156711 - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02334839 - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction N/A
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Completed NCT01691404 - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) N/A
Terminated NCT01412216 - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance Phase 2
Completed NCT01319344 - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Phase 3
Completed NCT00990730 - Atherosclerosis in Rheumatoid Arthritis N/A
Completed NCT00987974 - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury Phase 4
Completed NCT00848302 - Endothelial Function in Human Arteries Early Phase 1
Completed NCT00532844 - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction Phase 2
Completed NCT00376246 - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Phase 4
Completed NCT00775099 - Combustion Derived Air Pollution and Vascular Function N/A